StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)
by Doug Wharley · The Cerbat GemAnalysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Down 6.9 %
NASDAQ AKTX opened at $2.98 on Monday. The business’s 50-day moving average price is $3.57 and its two-hundred day moving average price is $2.60. Akari Therapeutics has a 12 month low of $1.08 and a 12 month high of $4.40.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
See Also
- Five stocks we like better than Akari Therapeutics
- What is an Earnings Surprise?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Buy P&G Now, Before It Sets A New All-Time High
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges